About
FutuRx was founded by Johnson & Johnson Innovation – JJDC, Takeda Pharmaceutical Company, through its venture group Takeda Ventures Inc.-TVI and OrbiMed Israel Partners together with the Israeli Innovation Authority of the Ministry of Economy and later joined by Leaps by Bayer, the impact investments unit of Bayer AG.
The FutuRx incubator is dedicated to the inception of early-stage biopharma ventures based on cutting edge science and supporting them in successful drug development
FutuRx strives to be a catalyst for drug development by bridging the gap between concept and proof of concept through its dedicated system and structure. FutuRx's management, together with its founders, will establish and fully support companies via its in-house laboratory and management facility.
FutuRx provides a unique model for supporting early-stage innovation, by combining expertise of FutuRx management team, and global capabilities of the founders, teamed with the Technological Incubators Program at the Israeli Innovation Authority.
Companies established by FutuRx benefit from professional assistance by industry leading experts. These global capabilities facilitate the development of innovative technologies, on the way to safely turning them into cutting-edge products for the benefit of patients and healthcare providers.
Portfolio · 23
Investment activity
1 portfolio exit on record.
Portfolio by sector
Q&A
- What is FutuRx's primary investment focus?
- FutuRx is an incubator dedicated to the inception of early-stage biopharma ventures based on cutting-edge science, supporting them in successful drug development. Their portfolio is entirely concentrated in the Health Tech & Life Sciences sector.
- Which organizations founded FutuRx?
- FutuRx was founded by Johnson & Johnson Innovation – JJDC, Takeda Pharmaceutical Company (through Takeda Ventures Inc.-TVI), OrbiMed Israel Partners, and the Israeli Innovation Authority of the Ministry of Economy. Leaps by Bayer later joined as an impact investment unit.
- What investment stages does FutuRx typically target?
- FutuRx primarily targets Pre-Seed, Seed, and A Round investments. According to startupim data, they have made 15 Seed investments and 1 Pre-Seed investment.
- Can you name some notable companies in FutuRx's portfolio?
- FutuRx has invested in companies such as BiomX, which focuses on microbiome therapies for chronic diseases, and Mitoconix Bio, which develops therapeutics for neurodegenerative diseases.
- Has FutuRx had any notable exits?
- Yes, FutuRx had an exit in November 2019 when BiomX completed a reverse merger with Chardan Healthcare Acquisition Corp and went public on the NYSE.
- What is the typical check size for FutuRx's investments?
- FutuRx's investment range for disclosed rounds is between $2.7 million and $3.6 million.
- Who is the CEO of FutuRx?
- Lianna Patt serves as the CEO of FutuRx.
- Where is FutuRx headquartered?
- FutuRx is headquartered in Ness Ziona, Israel.
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | futurx.co.il/ |
|---|---|
| linkedin.com/company/28173788 |
Identifiers & details
| Founded | 2014 |
|---|
Radar intelligence
Publications (Crossref)
| Works | 2 |
|---|
Web history (Wayback)
| Domain | futurx.co.il |
|---|
Certificate / subdomain footprint
| Subdomains | 10 |
|---|